title: Emerging treatments in neurogastroenterology: Acotiamade, a novel treatment option for functional dyspepsia.
abstract: Acotiamide hydrochloride (Z-338) is a new therapeutic agent for functional dyspepsia (FD). In 2013, the use of acotiamide was approved by the Japanese health insurance system.
  
  
  
  The aim of this review is to summarize the present staus of basic and clinical approach to acotiamide for the treatment of functional dyspepsia. The agent inhibits acetylcholinesterase in vitro and enhances muscle motility ex vivo. In phase-II studies, 100 mg three times daily (t.i.d.) was determined to be the optimal dose for the treatment of FD. In phase-III studies, overall treatment efficacy (OTE) was significantly better in the acotiamide group (52.2%) than in the placebo group (34.8%). However, the mechanism of its efficacy needs to be further elucidated. Acotiamide effectively improved FD symptoms, particularly postprandial distress syndrome symptoms, without causing major adverse effects.
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Matsushita
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Masaoka
authors.affiliation: Medical Education Center, Keio University School of Medicine, Tokyo, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Suzuki
mesh_terms: D001549:Benzamides / Q000494:pharmacology / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D004415:Dyspepsia / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D005762:Gastroenterology / Q000639:trends*; D005765:Gastrointestinal Agents / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D019518:Postprandial Period / Q000187:drug effects / Q000502:physiology; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D013844:Thiazoles / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D002800:Cholinesterase Inhibitors; D005765:Gastrointestinal Agents; D013844:Thiazoles; C410959:Z 338
keywords: acotiamide; functional dyspepsia; postprandial distress syndrome